Clinical Usability of Intranasal Glucagon in Treatment of Hypoglycemia
Clinical Usability of Intranasal Glucagon in Treatment of Hypoglycemia
Up to two hundred (200) adult participants with type 1 diabetes (T1D) aged 18 to 75 years
 will be selected for inclusion in the study. The target is to obtain treatment response and
 user-experience data following use of nasal glucagon (AMG504-1) in treating episodes of
 hypoglycemia. The population will be enriched to include participants who suffer from
 impaired hypoglycemia awareness.
This study is designed to evaluate the effectiveness of nasal glucagon (NG) administered
 under clinical use conditions in treating episodes of hypoglycemia in persons with T1D.

 This study also aims to assess the ease with which caregivers can administer the experimental
 medication in treatment of hypoglycemic events.

 The study will also generate data on the participants' assessment of local tolerability and
 provide information on immunogenicity of nasal glucagon with regards to the potential
 development of anti-glucagon antibodies.
Inclusion Criteria:

 -  Male or Female Person with diabetes (PWD) lives with or is in frequent contact with
 one or more caregivers who are available to administer the glucagon in case of an
 episode of severe or moderate hypoglycemia

 -  With a history of type 1 diabetes >1 year

 -  At least 18 years of age but not older than 75 years

 -  Body mass index (BMI) greater than or equal to 18.50 and below 35.00 kg/m2.

 -  PWD will be otherwise healthy according to medical history, general physical
 examination (including vital signs), nasal examination, and laboratory tests
 (biochemistry, hematology, and urinalysis).

 -  For female subjects, a urine pregnancy test must be negative.

 Exclusion Criteria:

 -  Presence or history of pheochromocytoma (i.e. adrenal gland tumor) or insulinoma.

 -  Use of a daily systemic beta-blockers, indomethacin, warfarin or anticholinergic
 drugs.